Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416624 · ClinicalTrials.gov registry record · Phase 2
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT00416624: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00416624 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 239 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00416624, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work in treating patients with anemia caused by chemotherapy.
Primary Outcome
A hematopoietic response was defined as Hb rise \>2 g/dL from baseline or achieving Hb ≥ 11.5 g/dL, whichever occurs first, in the absence of RBC transfusions within 14 days of measurement) during the treatment period
Interventions
- PROCEDURE quality-of-life assessment
- PROCEDURE fatigue assessment and management
- DRUG darbepoetin alfa
- DRUG epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00416624 record still lists
NCT00416624 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 4 interventions - of which quality-of-life assessment is the first listed.
NCT00416624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00416624 about?
NCT00416624 is a clinical study titled "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy". RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how...
What is the current status of trial NCT00416624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2007-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00416624?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), fatigue assessment and management (PROCEDURE), darbepoetin alfa (DRUG), epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00416624?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00416624's enrollment target sits among peer trials
239 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia